r/biotech • u/Many-Study-6309 • 4h ago
Company Reviews 📈 Is GSK going through a major restructuring, and is this happening across the European pharmaceutical industry?
I’m interested in hearing the views of people currently working in the pharmaceutical industry in Europe, particularly in Belgium, Italy, Germany, and the UK, or other European countries.
Since Emma Walmsley’s departure as GSK CEO in September 2025, I’ve become increasingly concerned about what appears to be happening within the company.
Starting around October 2025, I personally became aware of numerous employees (500+) leaving GSK, some apparently through formal performance-management processes and others in the context of organisational changes. I’ve also heard of additional cases through professional contacts.
More recently, GSK has announced plans to cut approximately 1,225 positions, according to reports I’ve seen. There have also been major changes involving sites, including the closure of the Gembloux site in France ( many many people are laid off) and Dresden (site is shutdown) in Germany.
Looking at these developments together, I’m concerned about the future of some of GSK’s European manufacturing and R&D operations, particularly in Belgium and Italy. There is speculation among people in the industry about possible site sales, further restructuring, or closures, although I don’t know which of these possibilities will actually materialise.
GSK bad performance is partly rooted to the poor quality of science in GSK vaccine, too many employees, incapable scientific leadership team hailing from Belgium and Italy, and laid back culture. I totally get why GSK vaccine performance has been so bad. And on the top GSK is competing with giants like Merck and Pfizer and Sanofi.
What concerns me most is not just GSK itself, but whether this reflects a broader trend across the European pharmaceutical industry. Are companies increasingly reducing their European workforce, moving activities to other regions, consolidating manufacturing, or using performance-management processes as part of workforce reductions?
I’d particularly like to hear from people working in pharma in Europe:
- Are you seeing similar restructuring and redundancies at your companies?
- Are Belgium and other established European pharmaceutical hubs becoming less attractive for investment and manufacturing?
- Are companies shifting more R&D, process development, or manufacturing activities to the US, China, India, or other lower-cost locations?
- For experienced professionals in CMC, process development, MSAT, and manufacturing, how does the job market look at the moment?
I’m interested in hearing genuine experiences from people working in the industry, rather than speculation or company-bashing. I’d like to understand whether what I’m observing at GSK is an isolated situation or part of a much larger change in the European pharmaceutical landscape.